(Q72785504)
Statements
Phase I trial of an interleukin-2 fusion toxin (DAB486IL-2) in hematologic malignancies: complete response in a patient with Hodgkin's disease refractory to chemotherapy (English)
I Tepler
G Schwartz
K Parker
J Charette
M E Kadin
T G Woodworth
1 February 1994